Recent Updates
Recently added Catalysts
ACRS Positive Sentiment

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Key Takeaway: Aclaris Therapeutics, Inc. announced its participation in the HC Wainwright "HCW@Home" series, featuring a fireside chat with CEO Neal Walker and the leadership team. Scheduled for May 16, 2025, at 1 PM EDT, the discussion will be accessible through a live and archived webcast on Aclaris' website. This engagement highlights Aclaris' commitment to showcasing its innovative work in immuno-inflammatory disease treatments.
Price reaction · baseline $1.31 (2025-05-08 close) · hit after-hours · clean, no other ACRS news in the window
day 0 close
-3.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a reputable virtual event increases visibility.
  • Opportunity for CEO to connect with potential investors.
  • Aclaris is focused on addressing unmet needs in immuno-inflammatory diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis

Full Press Release Details

WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright “HCW@Home” series.
The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT. A live and archived webcast of the event will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.
Aclaris Therapeutics Contact:

Frequently Asked Questions

What is Aclaris Therapeutics focused on?

Aclaris Therapeutics focuses on developing novel product candidates for immuno-inflammatory diseases.

When will Aclaris host a virtual fireside chat?

The virtual fireside chat is scheduled for May 16, 2025, at 1:00 PM EDT.

How can I access the fireside chat webcast?

The webcast will be available live and archived on Aclaris' Events page.

How long will the webcast be available?

The webcast will be accessible for at least 30 days on the Aclaris website.

How can I follow Aclaris Therapeutics online?

You can follow Aclaris on X (formerly Twitter) and LinkedIn for updates.

Last updated: May 9, 2025